PMEL and neoplasm: Two clinical studies registered on ClinicalTrials.gov evaluated chimeric DNA vaccines encoding xenogeneic tumor antigens such as mouse tyrosinase and gp100, leveraging the concept of breaking tolerance to self-antigens with high sequence homology to human proteins (Table 4).